Analysis of the efficacy and safety of new antihypertensive drugs in the management of chronic heart failure

• Georgiy K. Kamuschadze

Abstract

This article examines the efficacy of antihypertensive drugs in the treatment of chronic heart failure (CHF). The clinical data on the use of sodium-glucose cotransporter‑2 (SGLT2) inhibitors and angiotensin receptor-neprilysin inhibitors are compared with traditional treatment methods, including angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. A comparative analysis of the efficacy and safety of these drugs in reducing cardiovascular mortality and hospitalization rates in patients with CHF is provided. The safety profiles, including specific adverse effects associated with the use of newer drug classes, are discussed. The results indicate significant therapeutic potential for SGLT2 inhibitors and angiotensin receptor-neprilysin inhibitors, making them important additions to existing treatment strategies. Further research is needed to assess the long-term safety of these drugs in various populations.

Keywords: chronic heart failure; antihypertensive drugs; SGLT2 inhibitors; angiotensin receptor-neprilysin inhibitors; safety; efficacy; cardiovascular mortality; hospitalizations

References

1. WHO publishes statistics on the leading causes of death and disability worldwide for the period 2000–2019. WHO. URL: https://www.who.int/ru/news/item/09-12-2020-who-reveals-leading-causes-of-death-and-disability-worldwide-2000-2019 (date of access August 14. 2024). (in Russian)

2. Galyavich A.S., Galeeva Z.M., Baleeva L.V., Sabirzyanova A.A. Arterial hypertension as a cause of chronic heart failure. Arterial’naya gipertenziya [Arterial Hypertension]. 2022; 28 (2): 211–7. (in Russian)

3. Karpov Yu.A. Chronic heart failure: a new definition, new approaches to individuality. Atmosfera. Novosti kardiologii [Atmosphere. Cardiology News]. 2020; (4): 30–40. (in Russian)

4. Mascolo A., di Mauro G., Cappetta D., De Angelis A., Torella D., Urbanek K., et al. Current and future therapeutic perspective in chronic heart failure. Pharmacol Res. 2022; 175: 106035.

5. Di Palo K.E., Barone N.J. Hypertension and heart failure: prevention, targets, and treatment. Heart Fail Clin. 2020; 16 (1): 99–106.

6. Špinar J., Špinarová L., Vítovec J. Pathophysiology, causes and epidemiology of chronic heart failure. Vnitr Lek. 2018; 64 (9): 834–8.

7. Wintrich J., Berger A.K., Bewarder Y., Emrich I., Slawik J., Böhm M. Update on diagnostics and treatment of heart failure. Herz. 2022; 47 (4): 340–53.

8. Capriotti T., Micari M. Chronic heart failure treatment with the left ventricular assist device. Home Healthc Now. 2019; 37 (4): 190–7.

9. Jhund P.S., Fu M., Bayram E., Chen C.H., Negrusz-Kawecka M., Rosenthal A., et al.; PARADIGM-HF Investigators and Committees. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. Eur Heart J. 2015; 36 (38): 2576–84.

10. Khan M.N., Soomro N.A., Naseeb K., Bhatti U.H., Rauf R., Balouch I.J., et al. Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction. BMC Cardiovasc Disord. 2023; 23: 133.

11. McMurray J.J.V., Solomon S.D., Docherty K.F., Jhund P.S. The dapagliflozin and prevention of adverse outcomes in heart failure trial (DAPA-HF) in context. Eur Heart J. 2021; 42 (13): 1199–202.

12. Wagdy K. The EMPEROR-Reduced trial: SGLT2 inhibitors for heart failure get more support. Glob Cardiol Sci Pract. 2020; 2020 (3): e202031.

13. Results of the FIGARO-DKD study. Bayer. URL: https://www.bayer.ru/ru/news/20210528-figaro-dkd (date of access August 14. 2024). (in Russian)

14. Bakris G.L., Agarwal R., Anker S.D., Pitt B., Ruilope L.M., Nowack C., et al.; on behalf of the FIDELIO-DKD Study Investigators. Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial. Am J Nephrol. 2019; 50 (5): 333–44.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)